ADMA Biologics receives PDUFA date for RI-002
ADMA Biologics announces the FDA has acknowledged receipt of ADMA’s Sept. 28, 2018 BLA resubmission for RI-002. The FDA stated it considers the RI-002 BLA resubmission ‘a complete, Class 2 response’ and has established an action due date of April 2, 2019, under the Prescription Drug User Fee Act. October 17, 2018